Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Background and Aims HCV cure reduces but does not eliminate the risk of HCC. HCC
surveillance is recommended in populations where the incidence exceeds 1.5% per year. In …

Background & Aims Diabetes mellitus (DM) is known to increase the risk of hepatocellular
carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate …

Methods We included CHC patients from the T-COACH study who failed antiviral therapy.
We tracked the onset of HCC 1.5 years post-therapy by linking to Taiwan's cancer registry …

Hepatocellular carcinoma (HCC) is a major cause of cancer death in Taiwan, and in the past
30–40 years, Taiwan has been committed to its prevention and treatment. We aimed to …

Simple Summary Cost-effective, Hepatocellular carcinoma (HCC) risk-based surveillance
strategies should be established after achieving sustained virologic response (SVR) …

A total of 1,589 patients who had received interferon-based treatment were enrolled and
analyzed for the risk of hepatocellular carcinoma (HCC) in a real-world nationwide …

Introduction Taiwan has several hepatitis C virus (HCV) hyper-endemic areas. We aimed to
evaluate the effectiveness and safety of a collaborative HCV care system with an outreach …

Abstract Background Chronic hepatitis C (CHC) increases the risk of liver cirrhosis (LC) and
hepatocellular carcinoma (HCC). This nationwide cohort study assessed the effectiveness of …

Aims. Long‐term risk stratification using combined liver stiffness (LS) and clinically relevant
blood tests acquired at the baseline further beyond the sustained virologic response (SVR) …